In Brief
Refine Search
Pharmaceutical
Taiho Pharmaceutical, a subsidiary of Japanese drugmaker Otsuka, says that its partner, privately-held French drugmaker Servier, has received approval from the European Commission, of Lonsurf (trifluridine/tipiracil) in combination with bevacizumab. 2 August 2023
Pharmaceutical
The German economic development agency, Germany Trade and Invest (GTAI), has released a new podcast looking at recent developments in the life sciences industry in the country. 1 August 2023
Pharmaceutical
C4X Discovery (C4XD) has sold its remaining rights to the oral Orexin-1 receptor antagonist, C4X_3256, to fellow British firm Indivior, for $20 million. 1 August 2023
Biotechnology
Poland’s oncology specialist Ryvu Therapeutics has signed an agreement with the Medical Research Agency (ABM) for the financing of a project involving the execution of the RIVER-81 study. 31 July 2023
Pharmaceutical
Last Thursday, the US Food and Drug Administration (FDA) approved Ervebo, a vaccine for the prevention of Ebola virus disease caused by Zaire ebolavirus in individuals 12 months through 17 years of age. 29 July 2023
Biotechnology
Gilead Sciences has secured European approval for Trodelvy (sacituzumab govitecan) as a monotherapy for certain people with metastatic breast cancer. 28 July 2023
Biotechnology
US pharma major AbbVie and Calibr, a non-profit drug discovery division of Scripps Research, have expanded their strategic collaboration to advance several innovative pre-clinical and early-stage clinical assets across AbbVie's core therapeutic growth areas including immunology, oncology, neuroscience and other areas of interest. 27 July 2023
article
Japan’s Ono Pharmaceutical and US pharms major Bristol Myers Squibb have signed an agreement with the UK’s AstraZeneca and its subsidiary MedImmune and certain of their affiliates to completely and globally settle the infringement lawsuits and disputes over the PD-L1 and CTLA-4 antibody patents owned by Ono and BMS. 26 July 2023
Biotechnology
US biotech major Gilead Sciences has presented data to show that twice-yearly Sunlenca (lenacapavir) has a sustained impact on health-related quality of life in people with HIV. 25 July 2023
Pharmaceutical
Syros Pharmaceuticals shares fell 5.7% after-hours trading on Friday, after it revealed that US pharma giant Pfizer will terminate a license deal between the companies related to the development of novel therapies for two blood disorders. 25 July 2023
Biotechnology
Healthcare investor TVM Capital Life Science has joined forces with Tillotts Pharma to launch a new biotech company, Mage Biologics, backed by $28 million in financing. 21 July 2023
Pharmaceutical
The World Health Organization (WHO) is seeking to align its biowaiver policy with the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) guide. 21 July 2023
Biotechnology
FibroGen announced in a Securities and Exchange Commission (SEC) filing that it has approved a restructuring plan to lower the company’s operating expenses, with the news sending the firm’s shares down 7% to $2.38. 20 July 2023
Biotechnology
Shares of Belgo-Dutch autoimmune diseases specialist argenx jumped 8.6% to 475.30 euros, argenx, after it , announced today the pricing of a global offering of ordinary shares, which may be represented by American Depository Shares (ADSs). 19 July 2023
Pharmaceutical
USA-based Acadia Pharmaceuticals has expanded its current licensing agreement for trofinetide with Australian biotech Neuren Pharmaceuticals to acquire ex-North American rights to the drug as well as global rights in Rett syndrome and Fragile X syndrome to Neuren’s development candidate NNZ-2591. 15 July 2023
Biotechnology
The Wall Street Journal is reporting that Swiss drugmaker Roche is interested in acquiring an inflammatory bowel diseases drug from biotech firm Roivant Sciences for more than $7 billion. 14 July 2023
Pharmaceutical
Sweden's Vicore Pharma will install Ahmed Mousa as chief executive, replacing outgoing CEO Carl-Johan Dalsgaard, who is retiring. 14 July 2023
Biosimilars
Japanese drugmaker Chugai, Roche (the majority owner of Chugai), and Roche unit Genentech have filed a patent infringement lawsuit in the US District Court for the District of Massachusetts. 14 July 2023
Biotechnology
Genetic testing company GenePlanet has raised $22 million in a series B funding round led by BlackPeak Capita with participation from Darwin, Kolektor, Designed Impact Ventures and others. 13 July 2023
Pharmaceutical
German drugmaker STADA Arzneimittel is significantly expanding its European Consumer Healthcare portfolio by acquiring another range of well-established and leading local and regional consumer healthcare brands from French pharma major Sanofi in European countries. 13 July 2023
Biotechnology
HCW Biologics has announced a worldwide licensing agreement with WY Biotech to develop and commercialize one of its preclinical immunotherapy candidates. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of cardiovascular disease (CVD), has announced positive top-line data from its Phase III TANDEM clinical trial. 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
US clinical-stage biotech Vyriad has entered into a strategic collaboration with Swiss pharma giant Novartis to discover and develop in vivo chimeric antigen receptor (CAR) T-cell therapies. 21 November 2024
Biotechnology
The European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab), from US pharma giant Pfizer. 20 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Pharmaceutical
Anthony Harnden has been appointed as the new chair of the UK’s Medicine and Healthcare products Regulatory Agency (MHRA). 20 November 2024
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
Samsung Biologics, the biotech arm of Korea's Samsung Group, has announced a new manufacturing agreement worth $668 million. 20 November 2024
Biotechnology
Mirai Bio has announced the appointment of Jens Vogel as the company’s president and chief operating officer (COO). 20 November 2024
Pharmaceutical
Australia’s Therapeutic Goods Administration (TGA) yesterday warned that health professionals and consumers are advised that the oral antihistamine promethazine hydrochloride, sold as Phenergan and other generic brands, should not be used in children under six years of age. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze